x
CME-Tagline

Live Virtual Symposium: Laying to Rest Challenges in Managing Excessive Daytime Sleepiness in Patients with Obstructive Sleep Apnea or Narcolepsy - An Augmented Reality Experience

CMEO Webcast

Premiere Date: Monday, June 15, 2020

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. ABIM (MOC)
  5. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Tuesday, June 15, 2021

Faculty


Richard K. Bogan, MD, FCCP, FAASM Richard K. Bogan, MD, FCCP, FAASM 
President of Bogan Sleep Consultants, LLC
Chief Medical Officer, SleepMed Inc.
Director, SleepMed of South Carolina
Associate Clinical Professor
University of South Carolina School of Medicine
Columbia, SC
Associate Clinical Professor
Medical University of South Carolina
Charleston, SC

Michael J. Thorpy, MD Michael J. Thorpy, MD 
Professor of Neurology
Albert Einstein College of Medicine
Director, Sleep-Wake Disorders Center
Department of Neurology
Montefiore Medical Center
Bronx, NY
President, New York State Society of Sleep Medicine
Past President of the Sleep Section, Academy of Neurology

Statement of Need

Excessive daytime sleepiness (EDS) is a common symptom of obstructive sleep apnea (OSA) and narcolepsy. EDS is often associated with traffic accidents and occupational incidents, cognitive impairments, and increased risk of medical and psychiatric comorbidities, resulting in poorer quality of life (QoL) and increased mortality. Yet, the burden of EDS is often underestimated and devising effective strategies for management poses a significant challenge.

Advances in sleep medicine have offered increasingly detailed insight into the physiology of the sleep-wake cycle and its associated neurotransmitters. Subsequently, recent clinical trials have revealed the efficacy and safety of novel therapies in improving outcomes in patients with OSA or narcolepsy experiencing EDS. Translating these data into evidence-based practices is critical to reduce the burden of EDS.

This live virtual symposium will examine the impact of EDS on clinical outcomes, QoL, and psychosocial functioning as well as the subsequent need for early detection and effective treatment. In order to apply the latest scientific updates in sleep medicine, this symposium will feature Augmented Reality, enabling expert faculty to walk clinicians through the core physiological mechanisms involved in sleep and the means by which current and novel therapies exert their clinical impact. By navigating recent clinical trial data on these therapies, clinicians should be better able to apply the latest evidence to practice, optimizing the management of EDS in patients with narcolepsy or OSA.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Recognize the burden of Excessive Daytime Sleepiness (EDS) in patients with Obstructive Sleep Apnea (OSA) or narcolepsy.
  • Apply the science of sleep to novel treatments for EDS to optimize treatment selection.
  • Integrate efficacy and safety data into treatment decisions for EDS in patients with OSA or narcolepsy to improve QoL and functioning.

The following learning objectives pertain only to those requesting CNE credit:

  • Recognize the burden of EDS in patients with OSA or narcolepsy.
  • Explain the science of sleep for novel treatment decisions for EDS in patients with OSA or narcolepsy to improve QoL and functioning.
  • Recognize the burden of EDS in patients with OSA or narcolepsy.

Financial Support

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Target Audience

Sleep specialists, pulmonologists, psychiatrists, neurologists, primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs). Universal Activity Number: Live: 0376-0000-20-010-L01-P

Type: knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABPN MOC Credit:
ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

Learning Format:
Live activity

Royal College MOC Credit:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Bogan reports that he is a consultant for Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc. He participates in industry funded research with Avadel/Flamel Ireland LTD; Axsome Therapeutics, Inc.; Balance; Elsai Inc.; Fresca; Jazz Pharmaceuticals Inc.; and Merck & Co., Inc. He is on the speakers bureau for Jazz Pharmaceuticals, Inc.; and Merck & Co., Inc. He is a shareholder, member of the Board of Directors, and Chief Medical Officer and employee of SleepMed, Inc. He receives other financial or material support as a member of the Board of Directors, First Community Corporation, SC and National Sleep Foundation.

Dr. Thorpy reports he receives research support from Avadel Pharmaceuticals; Axsome Therapeutics, Inc.; Balance Therapeutics; Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for Avadel Pharmaceuticals; Axsome Therapeutics, Inc.; Balance Therapeutics; Eisai Inc.; Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty has been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

MM-098LS-061520-43